# Golimumab (MK-8259 / SCH900259) Treatment Withdrawal in Participants With Non-radiographic Axial Spondyloarthritis (GO-BACK) (MK-8259-038)

> **NCT03253796** · PHASE4 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 323 (actual)

## Conditions studied

- Spondyloarthritis

## Interventions

- **BIOLOGICAL:** Golimumab
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT03253796
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-07
- **Primary completion:** 2021-03-17
- **Final completion:** 2021-03-17
- **Target enrollment:** 323 (ACTUAL)
- **Last updated:** 2023-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03253796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03253796, "Golimumab (MK-8259 / SCH900259) Treatment Withdrawal in Participants With Non-radiographic Axial Spondyloarthritis (GO-BACK) (MK-8259-038)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03253796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*